Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease
The updated economic model has good predictive power, but validation against longer-term outcomes is still needed. Our analyses also demonstrate the importance of designing a model with sufficient flexibility such that the model allows for assessment of the impact of key sources of uncertainty on the value of DMAs. </AbstractSection> Copyright Springer International Publishing Switzerland 2014
Year of publication: |
2014
|
---|---|
Authors: | Guo, Shien ; Getsios, Denis ; Revankar, Nikhil ; Xu, Peng ; Thompson, Gwilym ; Bobula, Joel ; Lacey, Loretto ; Gaudig, Maren |
Published in: |
PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 32.2014, 11, p. 1129-1139
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Getsios, Denis, (2013)
-
Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia
Tolley, Keith, (2013)
-
Cost-Effectiveness Analyses in Multiple Sclerosis: A Review of Modelling Approaches
Guo, Shien, (2014)
- More ...